Lodoco
Payments companies reported to CMS as associated with Lodoco. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lodoco, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lodoco
These are the largest totals companies reported as associated with Lodoco. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Paul Ridker | Boston, MA | Cardiovascular Disease | $83,455.96 |
| Payal Kohli | Aurora, CO | Cardiovascular Disease | $15,021.66 |
| Andrew Freeman | Denver, CO | Cardiovascular Disease | $14,238.63 |
| Robert Quigley | Philadelphia, PA | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $9,500.00 |
| Amin Sabet | Fresno, CA | Cardiovascular Disease | $9,136.36 |
| Jimmy Kerrigan | Nashville, TN | Interventional Cardiology | $9,097.90 |
| Matthew Budoff | Torrance, CA | Cardiovascular Disease | $6,524.34 |
| Philip Nimoityn | Philadelphia, PA | Cardiovascular Disease | $6,403.53 |
| Henry Siu | New York, NY | Interventional Cardiology | $5,367.79 |
| Henock Saint Jacques | New York, NY | Cardiovascular Disease | $4,794.13 |
Prescribed Lodoco?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.